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Summary. Background and Objective. Gastric cancer is a frequent cause of cancer mortality. 
The prognosis of established tumor is unfavorable due to the propensity to spread and limited treat-
ment efficiency. Therefore, prevention has a high significance. We tested a population screening 
approach in order to identify families with an increased gastric cancer load for further surveillance. 
Material and Methods. Population screening was performed by questionnaire reaching 76.6% of 
the population. Hereditary gastric cancer (HGC) syndrome was diagnosed if 3 mutually first-degree 
relatives with gastric cancer were reported in the kindred. Additional group (HGC2) of families with 
2 first-degree relatives affected by gastric cancer was identified. 
Results. The HGC syndrome was diagnosed in 0.11%, but HGC2 syndrome, in 0.4% probands. 
The gastric cancer frequency among blood relatives was 25.2% (95% CI, 20.6%–30.4%) in HGC, 
but 16.0% (95% CI, 13.8%–18.5%) in HGC2 families. The mean age at diagnosis of cancer was 
56.9 years (95% CI, 53.4–60.3) in HGC and 62.5 years (95% CI, 60.1–64.8) in HGC2. The mean 
survival was 2.6 years (95% CI, 1.2–4.0). 
Conclusions. Population screening identifies reasonable number of families with a high frequen-
cy of gastric cancer. The frequency of gastric cancer and an unfavorable course characterized by low 
survival justify surveillance in families with 2 or 3 first-degree relatives affected by gastric cancer. 
Population screening provides the age characteristics of the respective tumors in order to adjust the 
surveillance schedule. 
Introduction
Gastric cancer is the second most common cause 
of cancer-related death in the world (1). In Baltic 
countries, the age-standardized incidence and mor-
tality rates of gastric cancer exceed the average val-
ues for Europe showing the urgency of the prob-
lem (2). Once the gastric cancer has developed, the 
course is unfavorable urging to search for means of 
cancer prevention. Diet and Helicobacter pylori are 
well-known environmental risk factors (3). How-
ever, increasing evidence suggests an important role 
of hereditary factors. In order to prevent hereditary 
cancer or at least to diagnose it early, follow-up 
programs could be offered to persons subjected to 
increased hereditary cancer risk. This necessitates 
well-planned strategy in order to find out the target 
patients.
A positive family cancer history is a well-known 
risk factor for developing gastric cancer (3–5). The 
relative risk is 1.3–2.2 if second- or first-degree rel-
atives are affected (3). Familial clustering is shown 
in approximately 10% of gastric cancer patients, and 
an autosomal dominant mode of inheritance with 
high penetrance is present in 3% of gastric cancer 
cases (6, 7). 
Familial gastric cancer is a complex syndrome. 
The concept of familial gastric cancer involves the 
use of the Lauren classification (8) distinguishing a 
diffuse and intestinal type of gastric cancer. The he-
reditary diffuse gastric cancer (HDGC) is character-
ized by autosomal dominant inheritance of E-cadher-
in/CDH1 mutations on chromosome 16q22 (9), first 
described in 3 Maori pedigrees with early-onset dif-
fuse gastric cancer (10), and later shown in European 
families with aggregation of diffuse but not intesti-
nal gastric cancer (11). Although initially truncating 
mutations were considered characteristic for HDGC 
(11), the clinically relevant CDH1 mutations includ-
ed also point mutations, small deletions, and inser-
tions along the entire coding sequence (9, 12, 13). 
Founder mutations are rare, described in the original 
Maori families as well as in group of families origi-
nating from Newfoundland. Recurrent mutations 
are due to both independent mutational events and 
common ancestry (9). CDH1 mutations are found in 
53.1% of families with 2 gastric cancer cases per kin-
dred in combination with at least one diffuse gastric 
cancer diagnosed before the age of 50 years (9, 12, 
14) or in 30%–50% of HDGC patients (6).
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The penetrance of CDH1 mutations determines 
the lifetime risk of gastric cancer and confers also the 
risk for lobular breast carcinoma in females. Some 
estimates have been published. The lifetime risk for 
gastric cancer in mutation carriers was estimated as 
70% (13). Alternatively, the cumulative risk of gas-
tric cancer by the age of 75 years was estimated as 
40% (95% confidence interval (CI), 12%–91%) for 
males and 63% (95% CI, 19%–99%) for females (9). 
Another groups have reported that the cumulative 
risk of gastric cancer by the age of 80 years was 67% 
(95% CI, 39%–99%) for men and 83% (95% CI, 
58%–99%) for women (15) or, similarly, the lifetime 
risk for gastric cancer was 63%–83% for females and 
40%–67% for males (16). The risk for lobular breast 
carcinoma in CDH1 mutation-carrying females is 
39%–40% (13, 15). The cumulative risk of female 
breast cancer by the age of 75 years was estimated 
as 52% (95% CI, 29%–94%) among the carriers of 
founder mutation in Newfoundland (9).
Variable diagnostic criteria can be applied. Fam-
ily with 3 cases of concordant cancer among first or 
second-degree blood relatives can be considered a 
high-risk cluster (17). HDGC is defined clinically 
as a family that fits one of the following criteria: ei-
ther 2 or more documented cases of diffuse gastric 
cancer in first- or second-degree relatives with at 
least one tumor diagnosed before the age of 50 or 
at least 3 documented cases of diffuse gastric cancer 
in first- or second-degree relatives independently of 
the age of onset (11). The criteria for CDH1 test-
ing are broader including also families with histo-
logically confirmed diffuse type of gastric cancer in 
single family member only, individuals with diffuse 
gastric cancer before 40 years of age irrespectively 
of family history, and families with diffuse gastric 
cancer and lobular breast cancer (18). The diagnos-
tic criteria of familial intestinal gastric cancer are 
adjusted to the incidence of gastric cancer in the 
corresponding population (11). In countries with a 
high gastric cancer rate, the criteria must be analo-
gous to the diagnostic criteria of hereditary non-
polyposis colorectal cancer (HNPCC): 1) at least 3 
relatives should have intestinal gastric cancer and 
one of them should be a first-degree relative of the 
other two; 2) at least 2 successive generations must 
be affected, 3) in one of the patients gastric can-
cer should be diagnosed before the age of 50. In 
contrast, in countries with a low incidence of gas-
tric cancer, the criteria should be following: 1) 2 or 
more documented cases of intestinal gastric cancer 
in first- or second-degree relatives with at least one 
tumor diagnosed before the age of 50, or 2) at least 
3 documented cases of intestinal gastric cancer in 
relatives at any age. Gastric cancer can also be a 
manifestation of HNPCC, Li-Fraumeni, familial ad-
enomatous polyposis, or Peutz-Jeghers syndromes, 
diagnosed by the corresponding criteria (11).
If the kindred correspond to the HDGC criteria, 
genetic testing should be advised involving search 
for CDH1 mutation in an affected patient and test-
ing of the healthy family members. The mutation 
carriers have a significant lifetime risk of diffuse 
gastric cancer (11, 13), known for its propensity to a 
submucosal spread, marked difficulties in early en-
doscopic diagnostics, and dismal prognosis in ad-
vanced stages. Therefore, an option of prophylactic 
gastrectomy can be considered in mutation carriers 
taking into account that the average age of clinically 
detectable gastric cancer development in HDGC 
kindred is 38 years (11, 13) but the age range is 
wide, from 16 to 82 years (13). The earliest lethal-
ity is recorded at 16–20 years (9, 10); therefore, the 
prophylactic gastrectomy might be suggested even 
in 20–30-year-old males. It is suggested to carry 
out the prophylactic gastrectomy 5 years earlier 
than the youngest age of gastric cancer diagnosis in 
the family (6). In females, the impact of gastrec-
tomy on pregnancy should be considered (9). Pro-
phylactic gastrectomy might carry 1%–2% mortal-
ity, 10%–20% major acute morbidity and inevitable 
late morbidity as weight loss, dumping syndrome 
and diarrhea. As the prophylactic operations would 
be performed in healthy young adults, the expected 
mortality and rate of complications might be lower 
than after curative gastrectomy for gastric tumor in 
an elderly person (11). In the stomachs removed by 
prophylactic gastrectomy, foci of diffuse cancer are 
frequent. The rate of such operations that in fact are 
curative, not prophylactic, is 76.5%–100% (13, 19). 
The agreement rate for prophylactic gastrectomy is 
45%–68% (9, 13). If the prophylactic gastrectomy 
is not acceptable, frequent surveillance gastroscopy 
with the best accessory techniques should be offered 
and combined by rigorous biopsies from any suspi-
cious lesion. The gastroscopy should be performed 
once or twice per year (6, 11). At least 15 random 
mucosal biopsies must be provided for pathology 
(13). However, insufficient efficacy of chromoen-
doscopy, endoscopic ultrasound, random biopsies, 
and PET-CT has been demonstrated in CDH1 mu-
tation carriers (13). Magnetic resonance imaging of 
breast is advocated (6). Thus, possibilities for sur-
veillance and intervention are already available and 
further development can be expected.
Considering the remarkable progress in the he-
reditary gastric cancer research, we designed our 
study with the aim to evaluate the importance of the 
hereditary gastric cancer by population frequency 
of the given syndrome, the associated cancer rate 
among blood relatives and impact of hereditary gas-
tric cancer in the total gastric cancer burden as well 
as the implications for cancer prevention assessing 
the health status of the identified persons and the 
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age characteristics of malignant tumor in the he-
reditary gastric cancer pedigrees. 
Material and Methods
The investigation was designed as population 
screening for hereditary cancer in the Valka district 
within the frames of the project “The development 
of hereditary cancer prophylaxis in Estonia and 
Latvia” co-financed by European Union Interreg 
IIIB Neighbourhood program. The Valka district 
is a geographic area in the northeast of Latvia. In 
collaboration with family physicians, 18 642 retro-
spective family cancer histories were collected from 
adult inhabitants representing 76.6% of the Valka 
population. The study was carried out from Sep-
tember 2005 until June 2007. The inclusion criteria 
comprised adult age, agreement to participate in the 
study, and registered place of residence within Valka 
district. No recruitment restrictions were applied for 
upper age limit, gender, ethnicity, or health status. 
Among the responders, there were 10 438 women 
(56.0%) and 7904 men (42.4%). The study was ap-
proved by the Central Commission of Medical Eth-
ics of Latvia. Written informed consent was ob-
tained from all patients. 
Information on family cancer history was collect-
ed using a questionnaire. The participants reported 
the presence and localization of tumors in kinsmen 
(father, mother, grandparents, siblings, children, 
grandchildren, siblings of parents, and other blood 
relatives), as well as the age of the patient in the 
time of the diagnosis.  If the patient died because of 
the tumor, the age at death was ascertained as well. 
Additional questions were asked about the treat-
ment modalities (e.g. radiation therapy and chemo-
therapy, extent of operation) of affected persons in 
order to verify the presence and location of cancer. 
The interview took 45 minutes to complete.
The filled questionnaires were analyzed in the 
Hereditary Cancer Institute, Rīga Stradiņš Univer-
sity. If hereditary cancer syndrome was diagnosed 
the corresponding persons were invited for repeated 
consultation to explain the syndrome entity and 
to provide written prophylactic recommendations 
concerning further surveillance and/or additional 
investigations. Hereditary gastric cancer (HGC) 
syndrome was diagnosed if 3 mutually first-degree 
blood relatives in kindred were diagnosed with 
gastric cancer. In addition, families with 2 mutu-
ally first-degree blood relatives affected by gastric 
cancer were identified and included into additional 
group (HGC2) for further analysis. 
Data obtained during secondary consultations 
were applied in order to identify mutually related 
families. In this way, the possibility to include any 
affected person repeatedly in the analysis due to 
several kindred relationships was eliminated.
Descriptive statistical analysis was performed 
using CIA (Confidence Interval Analysis) software 
(20). The population frequency of hereditary cancer 
syndrome was calculated as the ratio between the 
number of probands diagnosed with the syndrome 
and the size of study group. The data about the age 
of tumor diagnostics, age of tumor-related death, 
and survival of the affected persons were evaluated 
after detailed analysis of the relationships between 
different pedigrees. The cancer frequency in the re-
vealed families was calculated as the ratio between 
the number of affected blood relatives and the whole 
number of blood relatives in the corresponding 
blood line. The ratio between gastric cancer cases in 
HGC and/or HGC2 families and all reported gastric 
cancer cases in the pedigrees of study population 
was calculated as well. Data about cancer presence 
in spouses were recorded although excluded from 
the diagnostics of hereditary cancer. Spouse correla-
tion was calculated as the ratio of number of couples 
presenting a history of gastric cancer in both mem-
bers over the number of couples with at least one 
case of gastric cancer.
Results
The population screening disclosed 21 cases of 
hereditary gastric cancer syndrome (Fig. 1). In addi-
tion, 74 families were included in HGC2 group. This 
is the first documented evidence of HGC in Latvia. 
The population frequency of HGC was 0.11% (95% 
CI, 0.07%–0.17%) but of HGC2 – 0.4% (95% CI, 
0.32%–0.50%). HGC was the most frequent he-
reditary cancer syndrome in Valka population. The 
gastric cancer cases occurring within HGC families 
constituted 4.4% (95% CI, 3.5%–5.5%) but within 
combined group of HGC/HGC2 families – 13.9% 
(95% CI, 12.3%–15.7%) of all reported gastric can-
cer cases in the pedigrees of study population.
The age distribution of probands diagnosed 
with HGC and HGC2 is reflected in Fig. 2. The 
probands mostly were oncologically healthy them-
selves. In HGC syndrome, gastric cancer had been 
diagnosed in 1 proband – a 74-year-old female. 
Another proband, a 58-year-old female, had a his-
tory of breast cancer at the age of 41. Among the 74 
cases of HSC2 syndrome, 6 probands were affected 
by cancer in different locations. No cases of gastric 
cancer were observed. Endometrial cancer was re-
ported in 2 probands at the age of 53 and 63 years, 
respectively. There were also single cases of urinary 
bladder, prostate, ovarian, and colorectal cancer.
In total, 225 patients affected by gastric cancer 
were reported among blood relatives in HGC and 
HGC2 families. There were 126 men (57.5%; 95% 
CI, 50.9%–63.9%) and 93 women (42.5%; 95% CI, 
36.1%–49.1%) among the patients. In order to char-
acterize the course of HGC in Valka population, the 
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The frequency of gastric cancer among blood 
relatives was 18.2% (225/1235; 95% CI, 16.2%–
20.5%) in the whole group of HGC and HGC2, 
25.2% (76/302; 95% CI, 20.6%–30.4%) in HGC 
families and 16.0% (149/933; 95% CI, 13.8%–
18.5%) in HGC2.
Among HGC pedigrees, no other cancer cases 
were present in 8 of the 21 families featuring a can-
cer frequency of 27.4% (95% CI, 19.8%–36.5%). In 
the remaining HGC families, the following cancers 
were reported: 9 endometrial, 4 lung, 3 breast and 
3 colorectal cancer cases, single cases of unspecified 
gynecological, pancreatic, laryngeal and urinary 
bladder cancer as well as a single case of a hemato-
logical malignant tumor. In isolated cases, the ma-
lignant tumor was found in the brain or liver. 
Among HGC2 pedigrees, no other cancer cases 
were present in 24 of the 74 families having a gastric 
cancer frequency of 18.9% (95% CI, 14.4%–24.2%). 
In the remaining HGC2 families, the following can-
cers were reported: 12 endometrial and 2 cervical, 
11 lung, 7 colorectal, 6 breast, 6 renal, 5 urinary 
bladder, 3 ovarian, 3 unspecified gynecologic, 3 
pancreatic cancer, and 2 prostate cancer cases as 
well as 2 cases of head and neck cancer and single 
cases of esophageal and thyroid cancer. There were 
8 cases of brain tumor and 4 cases of hematologi-
cal malignancy. In 6 cases, the malignant tumor was 
found in the liver, but in 5 cases, in the abdominal 
cavity. In 9 cases, the location of cancer in the af-
fected person was not known to the proband. The 
frequency of most common extragastric tumors is 
presented in Table 2.
Combining all families affected by stomach can-
cer only vs. other families, the frequency of stom-
ach cancer was 21.4% (95% CI, 17.5%–26.0%) vs. 
16.9% (95% CI, 14.6%–19.6%).
The data describing the presence and exact lo-
cation of malignant tumors in both persons were 
obtained about 191 spouse couples belonging to 
the HGC pedigrees. Among these couples, at least 
1 case of gastric cancer was present in 83 families 
but there were only 3 cases of gastric cancer in both 
Fig. 1. Pedigree affected by hereditary stomach cancer 
manifesting in multiple persons in 2 generations
St, gastric cancer; d, dead. The age of cancer diagnostics is 
shown by number following the diagnosis, and the age of death 
is shown by the number, following the abbreviation “d”. 




























Fig. 2. The age distribution of probands diagnosed 
with hereditary gastric cancer syndrome 
HGC, hereditary gastric cancer; HGC2, families with 2 gastric 
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CI, confidence interval; HGC, hereditary gastric cancer, HGC2, families with 2 gastric cancer cases in first-degree relatives.
Table 1. The Characteristics of Hereditary Gastric Cancer Course by Population Screening Data
data about tumor diagnostics and cancer-related 
death in all affected persons from HGC and HGC2 
groups are represented in Table 1. There was a trend 
toward earlier age of tumor diagnostics in the HGC 
than in the HGC2. The age at death was statistically 
significantly lower in the HGC. Twelve affected per-
sons (5.4%; 95% CI, 3.1%–9.2%) were alive. The 
survival is presented in Table 1 as well. 




spouses. Thus, spouse correlation for gastric cancer 
was low (3.6%; 95% CI, 1.2%–10.1%).
Discussion
Gastric cancer is an important healthcare prob-
lem in Latvia. The age-standardized incidence rate 
of gastric cancer in Latvia is higher than in Europe-
an Union – 28.6 cases and 14.6 cases of gastric can-
cer (per 100 000) were reported in men and women, 
respectively, in Latvia. The EU age-standardized 
incidence rate is lower: 18.2 cases and 8.1 cases per 
100 000 are reported in men and women, respec-
tively (2). The dynamics of the gastric cancer inci-
dence rate in Latvia is shown in Figure 3. The age-
standardized mortality rate in Latvia is also at least 
twice higher than reported in the EU: 27.5 cases and 
12.0 cases per 100 000 in men and women, respec-
tively, versus 12.2 cases and 5.7 cases per 100 000 in 
men and women, respectively, in the EU (2). 
Population screening for hereditary cancer is a 
possibility to identify healthy persons at higher can-
cer risk thus giving an input in the early diagnostics 
and prevention of cancer (21) as performance of the 
prophylactic measures in this group could improve 
the results of cancer care. The population screening 
programs for hereditary cancer still are in the stage of 
development (22); therefore, our experience might 
be valuable for other centers planning and setting 
up programs with similar goals. Taking into account 
the abovementioned reasons and our objectives, we 
carried out the population screening for hereditary 
cancer in Valka district. In our experience, it was 
easily manageable. The population compliance dur-
ing screening program was sufficiently high (76.6%) 
in accordance with the published experience from 
the population screening in Poland, mentioning a 
population participation rate of 74.0% (22). 
The clinical diagnostics of HGC is embarrassed 
by the variety of diagnostic criteria. The criteria for 
hereditary diffuse and familial intestinal gastric can-
cer differ by the number of affected relatives, the de-
gree of kinship, and the presence or absence of age 
limit. However, in Latvian population, the informa-
tion about the cancer type in older relatives cannot 
be obtained due to several historical reasons. Such 
information is also too specific to be obtained from 
probands (18). Therefore, our criteria were based 
on the assumption that 3 cases of concordant cancer 
among the blood relatives points toward high risk of 
this tumor and 2 cases – toward moderate risk (18) 
and on the observations of minor relative risk differ-
ences in dependence on the cancer type (intestinal 
or diffuse) in affected probands (3). Although the 
published criteria of high risk familiar cancer clus-
ter include also the presence of particular cancer in 
second degree relatives (18), we limited our criteria 
to a more conservative approach diagnosing HGC 
or HGC2 syndromes on the basis of gastric cancer 
presence in mutually first-degree relatives.
The high frequency of gastric cancer in the 
identified Valka families as well as a statistically 
significant difference in cancer frequency among 
HGC and HGC2 groups shows the appropriateness 
of the applied clinical criteria based on the num-
ber of affected first-degree relatives. The differ-
ence also confirms the model of risk stratification 





















































HGC, hereditary gastric cancer; HGC2, group of families with 2 first-degree relatives affected by gastric cancer; 
CI, confidence interval. 
Table 2. The Frequency of Most Common Extra-Gastric Tumors Among Blood Relatives 
of Families Affected by Hereditary Gastric Cancer
Fig. 3. The dynamics of gastric cancer incidence rate 
in Latvia over years 1990–2010
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at least 3 affected first-degree blood relatives, and 
moderate-risk group, characterized by the presence 
of concordant cancer in 2 first-degree blood rela-
tives. Thus, a history of gastric cancer in 3 mutually 
first-degree relatives can show high risk, but in 2 
– moderate although elevated risk. Although dif-
ferentiation between hereditary diffuse and familial 
intestinal gastric cancer is important, it can be dif-
ficult if no ancient medical documentation (includ-
ing Lauren classification data) is available. In such 
situation, the applied criteria may help identify the 
need for surveillance.
Due to different methodology of calculation, it 
is not possible to compare exactly the frequency of 
gastric cancer in the affected Valka families with the 
lifetime risk for gastric cancer in CDH1 mutation 
carriers. Cautious illustrative comparison shows that 
the frequency is lower (13, 15) or close to the esti-
mates of gastric cancer risk (9) in CDH1 mutation 
carriers. An additional reason for the discrepancy is 
the fact that in our study all the blood relatives were 
included in the analysis as in the absence of muta-
tion analysis there was no possibility to exclude per-
sons without mutation. Naturally, this reduces the 
frequency estimates. 
The population screening brought the first docu-
mented evidence of hereditary and familial gastric 
cancer in Latvia. In a hypothetic population that 
would be equal in size to the population of Latvia 
but have the same ethnic, gender and age composi-
tion as Valka population, the detected population 
frequency would be equivalent to 2524 probands 
affected by definitive HGC syndrome and 9178 
probands affected by HGC2 syndrome.  
The frequency of gastric cancer both in HGC 
and HGC2 pedigrees exceeds the cumulative risk 
(0–74 years) in the European Union constituting 
1.62% in men and 0.68% in women (23). Accord-
ingly, surveillance should be offered to both groups. 
It should be started early as the youngest cases of 
gastric cancer in the identified families were diag-
nosed early – at 30 years and 34 years, respectively, 
in the HGC and HGC2 groups. Even earlier cancer 
development (at 16–20 years) has been described 
(9, 10, 13). The frequency of gastric cancer does not 
differ significantly in dependence on the presence of 
other cancers in the pedigree. Thus, these data do 
not influence the surveillance for gastric cancer. En-
dometrial cancer is the most common extragastric 
cancer. As its frequency exceeds the cumulative risk 
in European Union females (aged 0–74 years) con-
stituting 1.5% (23), surveillance can be considered 
especially if a family history is remarkable for the 
presence of endometrial cancer. The combination 
of gastric and endometrial cancer and brain tumors 
may suggest a peculiar variant of Lynch syndrome 
in a subgroup of HGC (24, 25).
Although the familial risk might be explained 
not only by heredity but also by shared environ-
mental factors the applied criteria allow detecting 
a risk group and could be recommended for practi-
cal use. However, the low spouse correlation points 
toward an importance of the genetic background. 
The role of environmental factors was not analyzed 
in the present study as such information would not 
be reliable regarding older medical information. It 
should also be emphasized that analysis of familial 
predisposition does not exclude the interaction be-
tween genetic and environmental factors.
The age distribution of the probands showed 
a wide plateau at the age interval of 30–70 years. 
As the mean age of cancer diagnostics in HGC and 
HGC2 pedigrees was 56.9 and 62.5 years, respec-
tively, at least part of the probands were younger, and 
thus, surveillance would be started at proper time. 
The oncological health status of probands also was 
appropriate for the surveillance as only 1 proband 
has gastric cancer herself. However, the seemingly 
beneficial health status of probands might partially 
be attributable to the rapid course of gastric cancer 
eliminating the affected persons from the popula-
tion and decreasing their chance to be included in 
the population screening as probands. The course 
of the tumor was aggressive – only 5.4% (95% CI, 
3.1%–9.2%) of the affected persons were alive at the 
time of population screening. The mean survival 
was only 2.5 years. 
The gastric cancer in HGC and HGC2 families 
in Valka population constitutes 13.9% (95% CI, 
12.3%–15.7%), but in HGC – 4.4% (95% CI, 3.5%–
5.5%) of all reported gastric cancer cases. These 
values slightly exceed the published estimates (6) 
describing familial clustering in 10% of gastric can-
cer patients and an autosomal dominant mode of 
inheritance in 3% of patients. The high frequency 
of gastric cancer in the identified families confirms 
the expedience of the used criteria; therefore, the 
higher finding could be considered true for Valka 
population. It is possible that a higher proportion 
of hereditary cancer in a particular location can be 
expected in a population subjected to general a high 
frequency of this cancer (2) as the environmental 
carcinogenic factors lessen the influence of the evo-
lutionary pressure striving to eliminate the carriers 
of harmful mutations.
The high frequency of gastric cancer in the af-
fected families, the unfavorable course, and low 
survival demand preventive means. Biannual chro-
moendoscopy with multiple biopsies can be offered. 
Surgical prophylaxis in the setting of genetic test-
ing for CDH1 mutations could become an effective 
solution for hereditary diffuse gastric cancer. Thus, 
population screening has identified hereditary and 
familial gastric cancer as an important, previously 
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unrecognized problem that can be approached by 
surveillance and surgery.
Conclusions
Hereditary gastric cancer is an important goal in 
oncology with significant implications for preven-
tion. Up to 13.2% of gastric cancer cases potentially 
could be prevented identifying the target families 
by a population screening approach with a simple 
questionnaire. The gastric cancer frequency among 
blood relatives in these families is significantly in-
creased reaching 25.2%. The number of affected 
blood relatives is an important diagnostic criterion. 
The high frequency of gastric cancer and an unfa-
vorable course characterized by low survival, justify 
surveillance in the families with 2 or 3 gastric cancer 
cases among first-degree blood relatives. The rec-
ommendation for surveillance is further enhanced 
by the possibility to start observation in healthy 
probands and the population frequency of the syn-
drome of 0.54% not posing a great burden on the 
healthcare system.
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